High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
Clinical trial NCT06652048 · RECRUITING
Trial details
- NCT number
- NCT06652048
- Sponsor
- Jialei Wang
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-01
- Primary completion
- 2026-12-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.